Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Nuvation Bio stock | $14.22

Learn how to easily invest in Nuvation Bio stock.

Nuvation Bio Inc
NYSE: NUVB - USD
BIOTECHNOLOGY
$8.64
+$0.04 (+0.47%)

Nuvation Bio Inc is a biotechnology business based in the US. Nuvation Bio shares (NUVB) are listed on the NYSE and all prices are listed in US Dollars. Nuvation Bio employs 38 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Nuvation Bio

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NUVB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Nuvation Bio stock price (NYSE: NUVB)

Use our graph to track the performance of NUVB stocks over time.

Nuvation Bio shares at a glance

Information last updated 2021-07-28.
Latest market close$14.22
52-week range$8.15 - $15.23
50-day moving average $9.74
200-day moving average $10.98
Wall St. target price$17.80
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Nuvation Bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Nuvation Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Nuvation Bio price performance over time

Historical closes compared with the close of $14.22 from 2021-05-28

1 week (2021-07-22) N/A
1 month (2021-07-02) 51.28%
3 months (2021-04-30) 27.08%
6 months (2021-01-29) N/A
1 year (2020-07-29) N/A
2 years (2019-07-29) N/A
3 years (2018-07-29) N/A
5 years (2016-07-29) N/A

Nuvation Bio financials

Gross profit TTM $0
Return on assets TTM -7.3%
Return on equity TTM -11.54%
Profit margin 0%
Book value $3.71
Market capitalisation $1.9 billion

TTM: trailing 12 months

Shorting Nuvation Bio shares

There are currently 5.8 million Nuvation Bio shares held short by investors – that's known as Nuvation Bio's "short interest". This figure is 22% up from 4.7 million last month.

There are a few different ways that this level of interest in shorting Nuvation Bio shares can be evaluated.

Nuvation Bio's "short interest ratio" (SIR)

Nuvation Bio's "short interest ratio" (SIR) is the quantity of Nuvation Bio shares currently shorted divided by the average quantity of Nuvation Bio shares traded daily (recently around 1.0 million). Nuvation Bio's SIR currently stands at 5.56. In other words for every 100,000 Nuvation Bio shares traded daily on the market, roughly 5560 shares are currently held short.

However Nuvation Bio's short interest can also be evaluated against the total number of Nuvation Bio shares, or, against the total number of tradable Nuvation Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nuvation Bio's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Nuvation Bio shares in existence, roughly 30 shares are currently held short) or 0.0498% of the tradable shares (for every 100,000 tradable Nuvation Bio shares, roughly 50 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Nuvation Bio.

Find out more about how you can short Nuvation Bio stock.

Nuvation Bio share dividends

We're not expecting Nuvation Bio to pay a dividend over the next 12 months.

Nuvation Bio overview

Nuvation Bio Inc. , a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting CDK2, CDK4, and CDK6. It is also developing NUV-868, a selective inhibitor of the BET family of epigenetic transcriptional regulators; NUV-569, a differentiated selective inhibitor of the Wee1 kinase; NUV-1182, an adenosine receptor inhibitor; and DDC platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to androgen receptor-expressing cancer cells , as well as PARP inhibitor to ER-expressing cancer cells. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019.

Frequently asked questions

What percentage of Nuvation Bio is owned by insiders or institutions?
Currently 27.299% of Nuvation Bio shares are held by insiders and 67.521% by institutions.
How many people work for Nuvation Bio?
Latest data suggests 38 work at Nuvation Bio.
When does the fiscal year end for Nuvation Bio?
Nuvation Bio's fiscal year ends in December.
Where is Nuvation Bio based?
Nuvation Bio's address is: 1500 Broadway, New York, NY, United States, 10036

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site